Neuroproteomics as a Tool for Understanding Schizophrenia

Daniel Martins-de-Souza holds a PhD in Biochemistry and Molecular Biology and is an Associate Professor of Biochemistry and Head of Proteomics at the University of Campinas (UNICAMP), in Brazil. Daniel´s postdoctoral training was carried out in the Max Planck Institute of Psychiatry in Germany and at the University of Cambridge, in the UK. For two years, Daniel was Principal Investigator in the Dept. of Psychiatry and Psychotherapy of the Ludwig Maximilians University (LMU), just before becoming a Professor. Daniel was elected Affiliated Member of the São Paulo Academy of Sciences in 2019 and Affiliated Member of the Brazilian Academy of Sciences in 2017. He is part of the Editorial Board of seven indexed journals and Associate Editor for npj Schizophrenia. His main expertise is on proteomics and systems biology tools to investigate molecular mechanisms involved in mental disorders.

• 1. Postmortem brains: what can proteomics tell us about the sources of schizophrenia?.- 2. What can we learn from animal models to study schizophrenia?.- 3. Modeling schizophrenia in vitro: challenges and insights on studying brain cell.- 4. Schizophrenia outside the brain.- 5. Molecular features triggered by antipsychotic medication in brain cells.- 6. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia.- 7. Molecular findings guiding the modulation of the endocannabinoid system as a potential target to treat schizophrenia.- 8. Metabolomics: A powerful tool to understand the schizophrenia biology.- 9. Modulating specific pathways in vitro to understand the synaptic dysfunction of schizophrenia.- 10. Proteomics and schizophrenia: the evolution of a great partnership.